+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

All Ages
All Genders
ID07341321

Evaluation of mRNA COVID-19 Vaccination Impact on Immune Checkpoint Therapy Outcomes in Hepatocellular Carcinoma Patients A Multicenter Retrospective Cohort Study in Austria

Led by Medical University of Graz · Updated on 2026-10-08

200

Participants Needed

5

Research Sites

21 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating how receiving an mRNA COVID-19 vaccine within 3 months before starting immune checkpoint inhibitor ICI therapy affects treatment response in patients with hepatocellular carcinoma HCC, an advanced liver cancer. This retrospective cohort study aims to understand if vaccination improves overall response to ICIs and explores related outcomes like survival and safety. The study is conducted across multiple centers in Austria where COVID-19 vaccination programs have been widely implemented. Participants include patients with confirmed HCC undergoing ICI therapy, divided into those vaccinated with an mRNA COVID-19 vaccine within 100 days before treatment and those not vaccinated in that timeframe. The study compares these groups to assess responses using imaging criteria and clinical data. Secondary aims evaluate survival times, progression rates, and safety outcomes such as immune-related adverse events and treatment discontinuations. During the study, researchers review existing electronic medical records, imaging response assessments, and clinical data for up to four years. They measure the best overall response using mRECIST criteria as the primary outcome and also track overall survival, progression-free survival, and time to progression. Safety data, including steroid use and toxicity leading to treatment stop, are also analyzed. The study does not involve active treatment administration but observes outcomes retrospectively.

CONDITIONS

Brief Title

SARS-CoV-2 mRNA Vaccination in Patients With Hepatocellular Carcinoma Treated With Immune Checkpoint Inhibitors

Research Team

F

Florian Rainer, MD

V

Vanessa Stadlbauer, Univ. Prof. MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here